Delbios Pharmaceuticals, a new spin-off company from ICMAB-CSIC to develop innovative nanomedicines
The UAB Research Park welcomes Delbios Pharmaceuticals SL, a new biotechnology company spin off from the Barcelona Institute of Materials Science (ICMAB-CSIC). The company aims to bring innovative nanomedicines from advanced preclinical stages to early clinical development, translating cutting-edge research into real therapeutic solutions.
Delbios Pharmaceuticals is a spin-off of the Nanomol-Bio research group at ICMAB-CSIC. The company focuses on bringing academic research to market by taking nanotechnology-based pharmaceutical products from advanced preclinical stages to the early phases of clinical development.
The new company has recently obtained funding from the Neotec 2025 Programme, which is promoted by the Centre for Technological Development and Innovation (CDTI). This competitive grant is aimed at technology-based start-ups with a high level of scientific innovation. This support will enable Delbios to consolidate its business project and accelerate the development of new therapies.
Delbios Pharmaceuticals was founded by researchers Nora Ventosa, Elisabet González and Judit Tomsen, from the Nanomol-Bio group, together with Nanomol Technologies SL executives Santi Sala and Alba Córdoba, a company also based in the UAB Research Park. Delbios’ business model is based on acquiring patent licenses for products primarily originating from the Nanomol-Bio research group at ICMAB-CSIC, sometimes in collaboration with other academic institutions, hospitals, and companies. These nanomedicines are advanced to early clinical stages and subsequently licensed out to pharmaceutical companies (out-licensing).
The company has emerged within the framework of the European Nano4Rare project, funded by the European Innovation Council (EIC) under the EIC Transition programme. The project will complete the preclinical phase of nanoGLA, a liposomal-based nanopharmaceutical for the treatment of Fabry disease. nanoGLA was designated as an Orphan Medicinal Product by the European Medicines Agency (EMA) in 2021.
The incorporation of Delbios Pharmaceuticals into the UAB Research Park reinforces our position as a leading hub for the establishment and expansion of research-driven enterprises, particularly in the areas of biomedicine and health technologies, and cements the UAB campus as a benchmark for scientific innovation and knowledge transfer.
The founder team of Delbios Pharmaceuticals: Santi Sala, Judit Tomsen, Elisabet Gonzalez, Alba Córdoba and Nora Ventosa
More news
